| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Insider buying and selling activity across 114 companies in the Pharmaceuticals industry. Part of the Health Care sector.
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Mar 24, 2015 | SUPN Supernus Pharmaceuticals, Inc. | Bryan Jones W. | VP Of Business Development | Sell | 1,900 | $12.00 | $22,800.00 | -2.7% | |
| Mar 23, 2015 | LLY Eli Lilly & Co | Lilly Endowment Inc | 10% Owner | Sell | 190,000 | $76.97 | $14,624,034.40 | - | |
| Mar 19, 2015 | CPIX Cumberland Pharmaceuticals Inc | Lawrence Thomas R | Director | Sell | 6,000 | $6.95 | $41,700.00 | -10.8% | |
| Mar 19, 2015 | ANIP Ani Pharmaceuticals Inc | Marken James G.47 | Vice President, Operations | Sell | 15,000 | $66.50 | $997,500.00 | -32.2% | |
| Mar 19, 2015 | ESPR Esperion Therapeutics, Inc. | Enright Patrick G75 | Director | Sell | 500,000 | $111.66 | $55,831,597.19 | -8.9% | |
| Mar 19, 2015 | NVS Novartis AG | Novartis Bioventures Ltd | 10% Owner | Sell | 49,141 | $14.50 | $712,544.50 | -0.5% | |
| Mar 18, 2015 | IRWD Ironwood Pharmaceuticals Inc | Fanucci Marsha | Director | Sell | 31,339 | $15.68 | $491,395.52 | -61.3% | |
| Mar 17, 2015 | IRWD Ironwood Pharmaceuticals Inc | Hecht Peter M | Chief Executive Officer | Sell | 200,000 | $15.62 | $3,123,154.48 | -1.6% | |
| Mar 16, 2015 | PCRX Pacira Biosciences, Inc. | Riker Lauren Bullaro76 | Executive Director, Finance | Sell | 5,000 | $95.34 | $476,700.00 | -69.2% | |
| Mar 13, 2015 | PCRX Pacira Biosciences, Inc. | Pace Gary W66 | Director | Buy | 1,000 | $93.83 | $93,829.90 | +5.7% | |
| Mar 12, 2015 | ANIP Ani Pharmaceuticals Inc | Marshbanks Tracy | Director | Sell | 210,000 | $63.00 | $13,230,000.00 | -27.6% | |
| Mar 12, 2015 | ANIP Ani Pharmaceuticals Inc | Raynor Daniel | Director | Sell | 200,000 | $63.00 | $12,600,000.00 | -38.2% | |
| Mar 12, 2015 | ANIP Ani Pharmaceuticals Inc | Arnold Charlotte C. | Vice President And CFO | Sell | 45,000 | $63.00 | $2,835,000.00 | -67.8% | |
| Mar 12, 2015 | ANIP Ani Pharmaceuticals Inc | Meridian Venture Partners II LP | 10% Owner | Sell | 300,000 | $63.00 | $18,900,000.00 | -11.3% | |
| Mar 12, 2015 | PCRX Pacira Biosciences, Inc. | Longenecker John P Phd | Director | Sell | 3,000 | $95.28 | $285,840.00 | -100% | |
| Mar 12, 2015 | ANIP Ani Pharmaceuticals Inc | Przybyl Arthur | President And CEO | Sell | 75,000 | $63.00 | $4,725,000.00 | -39.6% | |
| Mar 12, 2015 | IRWD Ironwood Pharmaceuticals Inc | Cook Joseph C Jr | Director | Sell | 5,883 | $15.54 | $91,395.82 | -1.5% | |
| Mar 10, 2015 | IRWD Ironwood Pharmaceuticals Inc | Roberts Bryan E | Director | Sell | 95,998 | $15.20 | $1,459,335.76 | -51.8% | |
| Mar 9, 2015 | LLY Eli Lilly & Co | Fry Stephen F | SVP, Hr &Diversity | Sell | 4,000 | $69.27 | $277,080.00 | -6.3% | |
| Mar 6, 2015 | INIS International Isotopes Inc | Grosso Christopher G | Director | Buy | 1,766,667 | $0.02 | $39,750.01 | +9.8% | |
| Mar 5, 2015 | JNJ Johnson & Johnson | Fasolo Peter61 | VP, Global Human Resources | Sell | 115,307 | $102.40 | $11,807,863.44 | -78.0% | |
| Mar 3, 2015 | IRWD Ironwood Pharmaceuticals Inc | Hecht Peter M | Chief Executive Officer | Sell | 63,442 | $15.75 | $999,361.56 | -0.4% | |
| Feb 27, 2015 | ANIK Anika Therapeutics, Inc. | Land Raymond J | Director | Sell | 4,621 | $39.49 | $182,483.29 | -23.3% | |
| Feb 26, 2015 | ANIK Anika Therapeutics, Inc. | Moran John C | Director | Sell | 2,500 | $39.61 | $99,025.00 | -11.5% | |
| Feb 20, 2015 | IRWD Ironwood Pharmaceuticals Inc | Cook Joseph C Jr | Director | Sell | 35,500 | $15.60 | $553,878.00 | -27.0% |
The blue line has two modes, toggled with the Relative and Absolute buttons:
Relative (default) shows cumulative industry performance with both the overall market and parent sector movements removed. When the line rises above 100, the industry is outperforming its sector; below 100 means underperforming. This is calculated using factor returns via weighted least squares (WLS) regression, isolating pure industry-specific behavior.
Absolute shows the total cumulative return of the industry including market and sector movement. This reflects what an investor actually experienced — an industry can show strong absolute gains even while underperforming its sector in relative terms.
Both views start at an index of 100. Other return drivers such as momentum, value, or size are deliberately retained in both modes, since these are part of what makes an industry behave the way it does and may reflect the conditions insiders are responding to.